drugset / Trial / NCT04866485
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multi-center phase 1 study. The trial, consisting of Part 1a dose confirmation and Part 1b dose expansion, is designed to evaluate the safety, tolerability, PK/PD and preliminary efficacy of HBM4003 in combination with pembrolizumab in patients with advanced NSCLC and other solid tumors.
Timeline
- Start
- 2021-06-14
- Primary completion
- 2023-02
- Completion
- 2023-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PORUSTOBART | Monoclonal antibody | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |